1. Executive Summary

    1.1. Fact.MR Research Analyzed

    1.2. Global Market – Wheel of Fortune (Opportunity Assessment)

    1.3. Global Market – Mega Trends

2. Market Introduction

    2.1. Global Market Definition

    2.2. Research Scope

3. Associated Indicators Assessment

    3.1. Market Dynamics

        3.1.1. Key Drivers and Trends

        3.1.2. Market Challenges

    3.2. Value Chain

    3.3. Comparison Chart

    3.4. Market – Opportunity Analysis

    3.5. Market Analysis – Investment Feasibility Index

    3.6. Market – PESTLE Analysis

    3.7. Market – Porter’s Five Forces Analysis

    3.8. Market – Market Positioning Assessment by Regions

    3.9. Market Analysis – Forecast Scenario

        3.9.1. Market Analysis – Forecast Factors

    3.10. Price Point Analysis by Region

    3.11. Regulations

    3.12. Voice of Customers

        3.12.1. Decision Purchase Attributes by Region

        3.12.2. Preferred Purchase Points

        3.12.3. Market Opportunity by Region

    3.13. STP Analysis and Go To Market Strategy (Recommendation)

4. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    4.1. Introduction

    4.2. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Type

        4.2.1. Normal-transit Constipation

        4.2.2. Slow-transit Constipation

    4.3. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Therapy

        4.3.1. Pharmacological Therapies

        4.3.2. Non-pharmacological Therapies

    4.4. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Treatment

        4.4.1. Medication

        4.4.2. Surgery

    4.5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Drug

        4.5.1. Serotonin-4 (5-Ht4) Receptor Agonist

        4.5.2. Guanylate Cyclase-C Agonist

        4.5.3. Laxatives

        4.5.4. Stimulants

    4.6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Route of Administration

        4.6.1. Oral

        4.6.2. Injectable

    4.7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by End User

        4.7.1. Hospitals

        4.7.2. Homecare

        4.7.3. Specialty Clinics

    4.8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Region

        4.8.1. North America

        4.8.2. Latin America

        4.8.3. Europe

        4.8.4. Japan

        4.8.5. APEJ

        4.8.6. MEA

5. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    5.1. Introduction

    5.2. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Country

        5.2.1. United States

        5.2.2. Canada

        5.2.3. Market Value Share and BPS Analysis by Country

        5.2.4. Y -o-Y Growth Projections by Country

        5.2.5. Absolute $ Opportunity by Country

        5.2.6. Market Attractiveness Assessment by Country

    5.3. North America Market Value (US$ Mn) and Volume (‘000 Units) by Type

        5.3.1. Market Value Share and BPS Analysis by Type

        5.3.2. Y-o-Y Growth Projections by Type

        5.3.3. Market Attractiveness Assessment by Type

    5.4. North America Market Value (US$ Mn) and Volume (‘000 Units) by Therapy

        5.4.1. Market Value Share and BPS Analysis by Therapy

        5.4.2. Y-o-Y Growth Projections by Therapy

        5.4.3. Market Attractiveness Assessment by Therapy

    5.5. North America Market Value (US$ Mn) and Volume (‘000 Units) by Treatment

        5.5.1. Market Value Share and BPS Analysis by Treatment

        5.5.2. Y-o-Y Growth Projections by Treatment

        5.5.3. Market Attractiveness Assessment by Treatment

    5.6. North America Market Value (US$ Mn) and Volume (‘000 Units) by Drug

        5.6.1. Market Value Share and BPS Analysis by Drug

        5.6.2. Y-o-Y Growth Projections by Drug

        5.6.3. Market Attractiveness Assessment by Drug

    5.7. North America Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration

        5.7.1. Market Value Share and BPS Analysis by Route of Administration

        5.7.2. Y-o-Y Growth Projections by Route of Administration

        5.7.3. Market Attractiveness Assessment by Route of Administration

    5.8. North America Market Value (US$ Mn) and Volume (‘000 Units) by End User

        5.8.1. Market Value Share and BPS Analysis by End User

        5.8.2. Y-o-Y Growth Projections by End User

        5.8.3. Market Attractiveness Assessment by End User

6. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    6.1. Introduction

    6.2. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Country

        6.2.1. Brazil

        6.2.2. Mexico

        6.2.3. Argentina

        6.2.4. Chile

        6.2.5. Peru

        6.2.6. Rest of Latin America

        6.2.7. Market Value Share and BPS Analysis by Country

        6.2.8. Y-o-Y Growth Projections by Country

        6.2.9. Absolute $ Opportunity by Country

        6.2.10. Market Attractiveness Assessment by Country

    6.3. Latin America Market Value (US$ Mn) and Volume (‘000 Units) by Type

        6.3.1. Market Value Share and BPS Analysis by Type

        6.3.2. Y-o-Y Growth Projections by Type

        6.3.3. Market Attractiveness Assessment by Type

    6.4. Latin America Market Value (US$ Mn) and Volume (‘000 Units) by Therapy

        6.4.1. Market Value Share and BPS Analysis by Therapy

        6.4.2. Y-o-Y Growth Projections by Therapy

        6.4.3. Market Attractiveness Assessment by Therapy

    6.5. Latin America Market Value (US$ Mn) and Volume (‘000 Units) by Treatment

        6.5.1. Market Value Share and BPS Analysis by Treatment

        6.5.2. Y-o-Y Growth Projections by Treatment

        6.5.3. Market Attractiveness Assessment by Treatment

    6.6. Latin America Market Value (US$ Mn) and Volume (‘000 Units) by Drug

        6.6.1. Market Value Share and BPS Analysis by Drug

        6.6.2. Y-o-Y Growth Projections by Drug

        6.6.3. Market Attractiveness Assessment by Drug

    6.7. Latin America Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration

        6.7.1. Market Value Share and BPS Analysis by Route of Administration

        6.7.2. Y-o-Y Growth Projections by Route of Administration

        6.7.3. Market Attractiveness Assessment by Route of Administration

    6.8. Latin America Market Value (US$ Mn) and Volume (‘000 Units) by End User

        6.8.1. Market Value Share and BPS Analysis by End User

        6.8.2. Y-o-Y Growth Projections by End User

        6.8.3. Market Attractiveness Assessment by End User

7. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    7.1. Introduction

    7.2. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Country

        7.2.1. EU-4 (Germany, France, Spain, and Italy)

        7.2.2. United Kingdom

        7.2.3. BENELUX

        7.2.4. NORDIC

        7.2.5. Rest of Europe

        7.2.6. Market Value Share and BPS Analysis by Country

        7.2.7. Y-o-Y Growth Projections by Country

        7.2.8. Absolute $ Opportunity by Country

        7.2.9. Market Attractiveness Assessment by Country

    7.3. Europe Market Value (US$ Mn) and Volume (‘000 Units) by Type

        7.3.1. Market Value Share and BPS Analysis by Type

        7.3.2. Y-o-Y Growth Projections by Type

        7.3.3. Market Attractiveness Assessment by Type

    7.4. Europe Market Value (US$ Mn) and Volume (‘000 Units) by Therapy

        7.4.1. Market Value Share and BPS Analysis by Therapy

        7.4.2. Y-o-Y Growth Projections by Therapy

        7.4.3. Market Attractiveness Assessment by Therapy

    7.5. Europe Market Value (US$ Mn) and Volume (‘000 Units) by Treatment

        7.5.1. Market Value Share and BPS Analysis by Treatment

        7.5.2. Y-o-Y Growth Projections by Treatment

        7.5.3. Market Attractiveness Assessment by Treatment

    7.6. Europe Market Value (US$ Mn) and Volume (‘000 Units) by Drug

        7.6.1. Market Value Share and BPS Analysis by Drug

        7.6.2. Y-o-Y Growth Projections by Drug

        7.6.3. Market Attractiveness Assessment by Drug

    7.7. Europe Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration

        7.7.1. Market Value Share and BPS Analysis by Route of Administration

        7.7.2. Y-o-Y Growth Projections by Route of Administration

        7.7.3. Market Attractiveness Assessment by Route of Administration

    7.8. Europe Market Value (US$ Mn) and Volume (‘000 Units) by End User

        7.8.1. Market Value Share and BPS Analysis by End User

        7.8.2. Y-o-Y Growth Projections by End User

        7.8.3. Market Attractiveness Assessment by End User

8. CIS & Russia Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    8.1. Introduction

    8.2. CIS & Russia Market Value (US$ Mn) and Volume (‘000 Units) by Type

        8.2.1. Market Value Share and BPS Analysis by Type

        8.2.2. Y-o-Y Growth Projections by Type

        8.2.3. Market Attractiveness Assessment by Type

    8.3. CIS & Russia Market Value (US$ Mn) and Volume (‘000 Units) by Therapy

        8.3.1. Market Value Share and BPS Analysis by Therapy

        8.3.2. Y-o-Y Growth Projections by Therapy

        8.3.3. Market Attractiveness Assessment by Therapy

    8.4. CIS & Russia Market Value (US$ Mn) and Volume (‘000 Units) by Treatment

        8.4.1. Market Value Share and BPS Analysis by Treatment

        8.4.2. Y-o-Y Growth Projections by Treatment

        8.4.3. Market Attractiveness Assessment by Treatment

    8.5. CIS & Russia Market Value (US$ Mn) and Volume (‘000 Units) by Drug

        8.5.1. Market Value Share and BPS Analysis by Drug

        8.5.2. Y-o-Y Growth Projections by Drug

        8.5.3. Market Attractiveness Assessment by Drug

    8.6. CIS & Russia Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration

        8.6.1. Market Value Share and BPS Analysis by Route of Administration

        8.6.2. Y-o-Y Growth Projections by Route of Administration

        8.6.3. Market Attractiveness Assessment by Route of Administration

    8.7. CIS & Russia Market Value (US$ Mn) and Volume (‘000 Units) by End User

        8.7.1. Market Value Share and BPS Analysis by End User

        8.7.2. Y-o-Y Growth Projections by End User

        8.7.3. Market Attractiveness Assessment by End User

9. Japan Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    9.1. Introduction

    9.2. Japan Market Value (US$ Mn) and Volume (‘000 Units) by Type

        9.2.1. Market Value Share and BPS Analysis by Type

        9.2.2. Y-o-Y Growth Projections by Type

        9.2.3. Market Attractiveness Assessment by Type

    9.3. Japan Market Value (US$ Mn) and Volume (‘000 Units) by Therapy

        9.3.1. Market Value Share and BPS Analysis by Therapy

        9.3.2. Y-o-Y Growth Projections by Therapy

        9.3.3. Market Attractiveness Assessment by Therapy

    9.4. Japan Market Value (US$ Mn) and Volume (‘000 Units) by Treatment

        9.4.1. Market Value Share and BPS Analysis by Treatment

        9.4.2. Y-o-Y Growth Projections by Treatment

        9.4.3. Market Attractiveness Assessment by Treatment

    9.5. Japan Market Value (US$ Mn) and Volume (‘000 Units) by Drug

        9.5.1. Market Value Share and BPS Analysis by Drug

        9.5.2. Y-o-Y Growth Projections by Drug

        9.5.3. Market Attractiveness Assessment by Drug

    9.6. Japan Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration

        9.6.1. Market Value Share and BPS Analysis by Route of Administration

        9.6.2. Y-o-Y Growth Projections by Route of Administration

        9.6.3. Market Attractiveness Assessment by Route of Administration

    9.7. Japan Market Value (US$ Mn) and Volume (‘000 Units) by End User

        9.7.1. Market Value Share and BPS Analysis by End User

        9.7.2. Y-o-Y Growth Projections by End User

        9.7.3. Market Attractiveness Assessment by End User

10. APEJ Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    10.1. Introduction

    10.2. APEJ Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Country

        10.2.1. China

        10.2.2. India

        10.2.3. Australia & New Zealand

        10.2.4. ASEAN

        10.2.5. South Korea

        10.2.6. Rest of APEJ

        10.2.7. Market Value Share and BPS Analysis by Country

        10.2.8. Y-o-Y Growth Projections by Country

        10.2.9. Absolute $ Opportunity by Country

        10.2.10. Market Attractiveness Assessment by Country

    10.3. APEJ Market Value (US$ Mn) and Volume (‘000 Units) by Type

        10.3.1. Market Value Share and BPS Analysis by Type

        10.3.2. Y-o-Y Growth Projections by Type

        10.3.3. Market Attractiveness Assessment by Type

    10.4. APEJ Market Value (US$ Mn) and Volume (‘000 Units) by Therapy

        10.4.1. Market Value Share and BPS Analysis by Therapy

        10.4.2. Y-o-Y Growth Projections by Therapy

        10.4.3. Market Attractiveness Assessment by Therapy

    10.5. APEJ Market Value (US$ Mn) and Volume (‘000 Units) by Treatment

        10.5.1. Market Value Share and BPS Analysis by Treatment

        10.5.2. Y-o-Y Growth Projections by Treatment

        10.5.3. Market Attractiveness Assessment by Treatment

    10.6. APEJ Market Value (US$ Mn) and Volume (‘000 Units) by Drug

        10.6.1. Market Value Share and BPS Analysis by Drug

        10.6.2. Y-o-Y Growth Projections by Drug

        10.6.3. Market Attractiveness Assessment by Drug

    10.7. APEJ Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration

        10.7.1. Market Value Share and BPS Analysis by Route of Administration

        10.7.2. Y-o-Y Growth Projections by Route of Administration

        10.7.3. Market Attractiveness Assessment by Route of Administration

    10.8. APEJ Market Value (US$ Mn) and Volume (‘000 Units) by End User

        10.8.1. Market Value Share and BPS Analysis by End User

        10.8.2. Y-o-Y Growth Projections by End User

        10.8.3. Market Attractiveness Assessment by End User

11. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    11.1. Introduction

    11.2. MEA Market Value (US$ Mn) and Volume (‘000 Units) by Country

        11.2.1. GCC Countries

        11.2.2. South Africa

        11.2.3. Turkey

        11.2.4. Israel

        11.2.5. Rest of MEA

        11.2.6. Market Value Share and BPS Analysis by Country

        11.2.7. Y-o-Y Growth Projections by Country

        11.2.8. Absolute $ Opportunity by Country

        11.2.9. Market Attractiveness Assessment by Country

    11.3. MEA Market Value (US$ Mn) and Volume (‘000 Units) by Type

        11.3.1. Market Value Share and BPS Analysis by Type

        11.3.2. Y-o-Y Growth Projections by Type

        11.3.3. Market Attractiveness Assessment by Type

    11.4. MEA Market Value (US$ Mn) and Volume (‘000 Units) by Therapy

        11.4.1. Market Value Share and BPS Analysis by Therapy

        11.4.2. Y-o-Y Growth Projections by Therapy

        11.4.3. Market Attractiveness Assessment by Therapy

    11.5. MEA Market Value (US$ Mn) and Volume (‘000 Units) by Treatment

        11.5.1. Market Value Share and BPS Analysis by Treatment

        11.5.2. Y-o-Y Growth Projections by Treatment

        11.5.3. Market Attractiveness Assessment by Treatment

    11.6. MEA Market Value (US$ Mn) and Volume (‘000 Units) by Drug

        11.6.1. Market Value Share and BPS Analysis by Drug

        11.6.2. Y-o-Y Growth Projections by Drug

        11.6.3. Market Attractiveness Assessment by Drug

    11.7. MEA Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration

        11.7.1. Market Value Share and BPS Analysis by Route of Administration

        11.7.2. Y-o-Y Growth Projections by Route of Administration

        11.7.3. Market Attractiveness Assessment by Route of Administration

    11.8. MEA Market Value (US$ Mn) and Volume (‘000 Units) by End User

        11.8.1. Market Value Share and BPS Analysis by End User

        11.8.2. Y-o-Y Growth Projections by End User

        11.8.3. Market Attractiveness Assessment by End User

12. Competitive Assessment

    12.1. Global Market Structure

    12.2. Global Market Competition – a Dashboard View

    12.3. Global Market Company Share Analysis

    12.4. Market Player Competition Footprint Matrix

    12.5. Key Participants Market Presence (Intensity Mapping) by Region

13. Company Profiles

    13.1. Bayer AG

        13.1.1. Overview

        13.1.2. Product Portfolio

        13.1.3. Profitability by Market Segments

        13.1.4. Sales Footprint

    13.2. Allergan

        13.2.1. Overview

        13.2.2. Product Portfolio

        13.2.3. Profitability by Market Segments

        13.2.4. Sales Footprint

    13.3. Bausch Health

        13.3.1. Overview

        13.3.2. Product Portfolio

        13.3.3. Profitability by Market Segments

        13.3.4. Sales Footprint

    13.4. Sanofi

        13.4.1. Overview

        13.4.2. Product Portfolio

        13.4.3. Profitability by Market Segments

        13.4.4. Sales Footprint

    13.5. Takeda Pharmaceutical Company

        13.5.1. Overview

        13.5.2. Product Portfolio

        13.5.3. Profitability by Market Segments

        13.5.4. Sales Footprint

    13.6. Sebela Pharmaceuticals

        13.6.1. Overview

        13.6.2. Product Portfolio

        13.6.3. Profitability by Market Segments

        13.6.4. Sales Footprint

    13.7. Ironwood Pharmaceuticals, Inc.

        13.7.1. Overview

        13.7.2. Product Portfolio

        13.7.3. Profitability by Market Segments

        13.7.4. Sales Footprint

    13.8. Albireo Pharma, Inc.

        13.8.1. Overview

        13.8.2. Product Portfolio

        13.8.3. Profitability by Market Segments

        13.8.4. Sales Footprint

    13.9. Sucampo Pharmaceuticals, Inc. (Mallinckrodt)

        13.9.1. Overview

        13.9.2. Product Portfolio

        13.9.3. Profitability by Market Segments

        13.9.4. Sales Footprint

    13.10. Janssen Pharmaceuticals, Inc.

        13.10.1. Overview

        13.10.2. Product Portfolio

        13.10.3. Profitability by Market Segments

        13.10.4. Sales Footprint

    13.11. Synergy Pharmaceuticals Inc.

        13.11.1. Overview

        13.11.2. Product Portfolio

        13.11.3. Profitability by Market Segments

        13.11.4. Sales Footprint

    13.12. Shandong Luoxin Pharmaceutical Group Stock Co., Ltd

        13.12.1. Overview

        13.12.2. Product Portfolio

        13.12.3. Profitability by Market Segments

        13.12.4. Sales Footprint

    13.13. Zydus Cadila

        13.13.1. Overview

        13.13.2. Product Portfolio

        13.13.3. Profitability by Market Segments

        13.13.4. Sales Footprint

    13.14. Boehringer Ingelheim International GmbH

        13.14.1. Overview

        13.14.2. Product Portfolio

        13.14.3. Profitability by Market Segments

        13.14.4. Sales Footprint

    13.15. Abbott Laboratories

        13.15.1. Overview

        13.15.2. Product Portfolio

        13.15.3. Profitability by Market Segments

        13.15.4. Sales Footprint

    13.16. GlaxoSmithKline Plc

        13.16.1. Overview

        13.16.2. Product Portfolio

        13.16.3. Profitability by Market Segments

        13.16.4. Sales Footprint

    13.17. Troikaa Pharmaceuticals Ltd

        13.17.1. Overview

        13.17.2. Product Portfolio

        13.17.3. Profitability by Market Segments

        13.17.4. Sales Footprint

    13.18. Lupin

        13.18.1. Overview

        13.18.2. Product Portfolio

        13.18.3. Profitability by Market Segments

        13.18.4. Sales Footprint

    13.19. East West Pharma

        13.19.1. Overview

        13.19.2. Product Portfolio

        13.19.3. Profitability by Market Segments

        13.19.4. Sales Footprint

    13.20. Ferring B.V.

        13.20.1. Overview

        13.20.2. Product Portfolio

        13.20.3. Profitability by Market Segments

        13.20.4. Sales Footprint

    13.21. Albireo Pharma, Inc.

        13.21.1. Overview

        13.21.2. Product Portfolio

        13.21.3. Profitability by Market Segments

        13.21.4. Sales Footprint

14. Assumptions and Acronyms Used

15. Research Methodology

※参考情報 慢性特発性便秘は、特定の病理的な原因がないにもかかわらず、慢性的に便秘状態が続く状態を指します。これは、日常生活に大きな影響を及ぼすことが多く、患者の生活の質を著しく低下させることがあります。便秘の定義は、通常、一週間に排便回数が三回未満であり、硬い便または排便時の疼痛を伴うことが一般的です。 慢性特発性便秘の主な種類には、機能性便秘、過敏性腸症候群に伴う便秘、そして慢性的な腹部痛を伴う便秘などがあります。これらはそれぞれ異なる症状や原因を持ちますが、いずれも特発的であり、他の病気によって引き起こされているわけではありません。慢性特発性便秘は、特に女性に多く見られ、年齢が上がるにつれてそのリスクが増加します。 治療には、生活習慣の改善や食事療法、薬物療法が用いられます。食事療法では、食物繊維を豊富に含む食品を増やすことが推奨されます。繊維質の摂取は、便のかさを増やし、腸の動きを促進する効果があります。水分補給も重要であり、十分な水分を摂取することが、便の柔らかさを保つために必要です。 運動も便秘の予防や改善に役立ちます。適度な運動を行うことで、腸の動きが活性化され、便通が促進されます。ストレス管理も重要な要素であり、リラクゼーションや趣味の時間を持つことが、便秘の改善に寄与することがあります。 薬物療法には、主に下剤が使用されますが、その種類は多岐にわたります。浸透圧性下剤や刺激性下剤、便軟化剤などがあり、患者の症状や状態に応じて選択されます。また、最近では、セロトニン受容体作動薬や、腸内細菌叢を調整するプロバイオティクスも注目されています。これらの薬剤は、腸の機能を改善し、便秘の症状を軽減する効果が期待されます。 慢性特発性便秘は、医療機関での診断と適切な治療が重要です。自己判断での対処は、逆に症状を悪化させる場合もあるため、専門医の診断を受けることが重要です。特に、高齢者や慢性的な基礎疾患を持つ患者においては、慎重な評価が求められます。 また、最近の研究では、腸内フローラのバランスが便秘に与える影響が注目されています。腸内細菌のバランスが乱れると、消化器系の機能が悪化し、便秘が生じることがあります。プロバイオティクスの摂取や、プレバイオティクスを含む食品を摂ることで、腸内環境を改善し、便秘の症状を和らげる可能性があるとされています。 さらに、慢性特発性便秘における新たな治療法として、経口薬や注射薬といった革新技術の研究も進んでいます。これには、腸の運動を促進する新しい作用機序を持つ薬剤が含まれ、今後の治療選択肢を広げる可能性があります。 慢性特発性便秘は、単なる「便が出ない」という症状に留まらず、患者にとっては身体的な苦痛や精神的なストレスにつながることがあります。そのため、適切な治療とケアにより、症状を軽減し、生活の質を向上させることが重要です。患者自身が自分の状態を理解し、医師と密に連携を取ることで、改善への道が開かれることが期待されます。適切な生活習慣や治療法を見つけることで、慢性特発性便秘を克服し、快適な日常生活を取り戻すことが可能です。

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/